Literature DB >> 33384889

Safety and Comfort of an Innovative Drug Delivery Device in Healthy Subjects.

Christian J F Bertens1, Suryan L Dunker2,3, Aylvin J A A Dias1,4, Frank J H M van den Biggelaar1,2, Rudy M M A Nuijts1,2, Marlies Gijs1.   

Abstract

Purpose: The aim of this study was to investigate safety and comfort of two versions of a placebo-microsphere filled ocular coil (straight and curved) in healthy subjects.
Methods: The study was a single-center intervention study. One ocular coil was placed in the inferior conjunctival fornix for the intended duration of 28 days. Forty-two healthy adult subjects were included. At baseline, 30 minutes, 8 hours, 24 hours, 48 hours, 7 days, 14 days, 21 days, and 28 days after insertion, examinations were performed, including slit lamp evaluation to score ocular redness, intraocular pressure measurement, visual acuity, tear secretion test, and questionnaires.
Results: The straight and curved ocular coils had a median retention time of 5 days and 12 days, respectively. After 48 hours, 57% and 81% subjects retained the straight and curved ocular coil, respectively. Four (19%) subjects with the straight coil and six (29%) with the curved coil completed the entire study period. Minor changes in ocular hyperemia were observed in both groups. On day 7, the straight coil was more comfortable than the curved coil with a visual analogue scale (VAS) score of 77 ± 21 compared to 94 ± 11 (P = 0.028), respectively. No other ocular adverse events were observed. Conclusions: Comfort and safety of the straight and curved ocular coil are high. Because the retention time is too short for long-term sustained drug release, the use in the perioperative or immediate postoperative period could prove to be more valuable. Translational Relevance: The ocular coil is a noninvasive, comfortable and safe short-term drug delivery device. Copyright 2020 The Authors.

Entities:  

Keywords:  clinical study; comfort and safety study; ocular coil; ophthalmology; placebo drug delivery device

Mesh:

Substances:

Year:  2020        PMID: 33384889      PMCID: PMC7757610          DOI: 10.1167/tvst.9.13.35

Source DB:  PubMed          Journal:  Transl Vis Sci Technol        ISSN: 2164-2591            Impact factor:   3.283


  36 in total

1.  Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring.

Authors:  James D Brandt; Harvey B DuBiner; Robert Benza; Kenneth N Sall; Gary A Walker; Charles P Semba
Journal:  Ophthalmology       Date:  2017-05-17       Impact factor: 12.079

Review 2.  Prevention of macular edema after cataract surgery.

Authors:  Laura H P Wielders; Jan S A G Schouten; Rudy M M A Nuijts
Journal:  Curr Opin Ophthalmol       Date:  2018-01       Impact factor: 3.761

Review 3.  Dropless Cataract Surgery: An Overview.

Authors:  Richard L Lindstrom; M Stewart Galloway; Andrzej Grzybowski; Jeffrey T Liegner
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 4.  Tear film, pharmacology of eye drops, and toxicity.

Authors:  R M Palmer; H E Kaufman
Journal:  Curr Opin Ophthalmol       Date:  1995-08       Impact factor: 3.761

Review 5.  Treatment of cystoid macular edema after cataract surgery.

Authors:  Laura H P Wielders; Jan S A G Schouten; Merel R Aberle; Verena A Lambermont; Frank J H M van den Biggelaar; Bjorn Winkens; Rob W P Simons; Rudy M M A Nuijts
Journal:  J Cataract Refract Surg       Date:  2017-02       Impact factor: 3.351

6.  Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery.

Authors:  Eric D Donnenfeld; J Steven Whitaker; Mitchell A Jackson; John Wittpenn
Journal:  J Cataract Refract Surg       Date:  2017-05       Impact factor: 3.351

7.  Evaluation of eyedrop administration by inexperienced patients after cataract surgery.

Authors:  Jella Angela An; Oscar Kasner; Deborah Anne Samek; Valérie Lévesque
Journal:  J Cataract Refract Surg       Date:  2014-09-22       Impact factor: 3.351

Review 8.  Cataract Drug Delivery Systems (Dropless vs. Nondropless Cataract Surgery).

Authors:  Michelle K Rhee; Francis S Mah
Journal:  Int Ophthalmol Clin       Date:  2016

9.  Capacity and tolerance of a new device for ocular drug delivery.

Authors:  Rachel T Pijls; Lars P J Cruysberg; Rudy M M A Nuijts; Aylvin A Dias; Leo H Koole
Journal:  Int J Pharm       Date:  2007-04-19       Impact factor: 5.875

10.  Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza™): results of a qualitative survey.

Authors:  Joseph P Gira; Reginald Sampson; Steven M Silverstein; Thomas R Walters; Jamie Lynne Metzinger; Jonathan H Talamo
Journal:  Patient Prefer Adherence       Date:  2017-03-08       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.